ClinicalTrials.gg
Sign In
Status unknownNCT03600259TAMIUpdated Nov 2, 2022

Tianjin Inpatient Acute Myocardial Infarction Registry

An observational study in Myocardial Infarction, Acute, sponsored by Tianjin Chest Hospital. Status unknown at 1 site in China. Per ClinicalTrials.gov, last updated 2022-11-02.

Sponsored by Tianjin Chest Hospital · Observational

The sponsor has not verified this record recently (last verified Nov 2022), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
13,000
Sex
All
01

Study summary

Acute myocardial infarction(AMI) is the most serious manifestation of coronary artery disease. AMI is characterized by high mortality, high disability, and high cost. However, multicenter research on AMI with large sample size in Tianjin or even China is limited. By including AMI in 36 hospitals,this multicenter study will capture the changes in epidemiological trends ,analyze the status of treatment in Tianjin, and explore the best treatment strategies.

02

Conditions studied

  • Myocardial Infarction, Acute

Keywords

  • Myocardial Infarction
  • Coronary Disease
  • Coronary Artery Disease
  • Myocardial Ischemia
03

In context

Myocardial Infarction

2,270 studies on the registry are indexed under Myocardial Infarction; 371 are open to participants now.

This study's planned enrollment of 13,000 is above the median of 568 across 814 observational studies indexed under Myocardial Infarction.

Browse Myocardial Infarction studies →

Lead sponsor

Tianjin Chest Hospital is the lead sponsor of 9 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Hospitalized patients with acute myocardial infarction from 36 hospitals in Tianjin were enrolled between January 2015 and January 2020

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized patients with acute myocardial infarction according to Cardiac biomarker values [Selective cardiac troponin (cTc) elevation and/or decline detection, at least one value exceeds the 99% reference limit (URL) and at least one of the following:（1）Symptoms of myocardial ischemia；（2）New or suspected new obvious ST-T changes or new left bundle branch block (LBBB)；（3） pathological Q waves；（4）Image evidence of recent loss of viable myocardium, or new regional wall motion abnormalities；（5）Coronary thrombosis confirmed by angiography or autopsy.]

Exclusion criteria

Exclusion Criteria:

  • Those who did not meet the diagnosis of acute myocardial infarction (no myocardial ischemia-related symptoms, elevation of markers of myocardial necrosis and imaging findings of myocardial infarction); those who met the inclusion criteria but refused to participate in the study; The researchers judged that the subjects had poor compliance and could not Complete follow-up as required.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
13,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Acute Myocardial Infarction
06

What researchers measure

Primary outcomes

  1. Cardiac death

    Due to recent cardiac causes (eg myocardial infarction, low-volume heart failure, fatal arrhythmias), any deaths from unknown and unexplained deaths and all surgical-related deaths (including treatment-related deaths) will be attributed to cardiac death.Unless there is a clear non-cardiological cause, all deaths are considered heart disease. Specifically, even patients with concurrent potentially fatal non-cardiac diseases (such as cancer, infections) who have any accidental death should be classified as having a heart attack.

    Time frame: 1 year

Secondary outcomes

  1. Major adverse cardiovascular events

    Composite of major adverse cardiovascular events (MACE) including cardiac death, heart failure, target vessel revascularization, recurrent myocardial infarction, stroke, severe bleeding

    Time frame: 10 days on average (during hospitalization)

  2. Major adverse cardiovascular events

    Composite of major adverse cardiovascular events (MACE) including cardiac death, heart failure, target vessel revascularization, recurrent myocardial infarction, stroke, severe bleeding

    Time frame: 1 month

  3. Major adverse cardiovascular events

    Composite of major adverse cardiovascular events (MACE) including cardiac death, heart failure, target vessel revascularization, recurrent myocardial infarction, stroke, severe bleeding

    Time frame: 3 months

  4. Major adverse cardiovascular events

    Composite of major adverse cardiovascular events (MACE) including cardiac death, heart failure, target vessel revascularization, recurrent myocardial infarction, stroke, severe bleeding

    Time frame: 6 months

  5. Major adverse cardiovascular events

    Composite of major adverse cardiovascular events (MACE) including cardiac death, heart failure, target vessel revascularization, recurrent myocardial infarction, stroke, severe bleeding

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Tianjin Chest Hospital
    Tianjin, Tianjin 300051, China
    Recruiting
08

References and documents

Publications

  • Gao MD, Zhang EY, Liu YY, Li XW, Xiao JY, Sun GY, Liu Y. Intracoronary pressure gradient measurement in acute myocardial infarction patients with the no-reflow phenomenon during primary percutaneous coronary intervention. Chin Med J (Engl). 2020 Apr 5;133(7):766-772. doi: 10.1097/CM9.0000000000000709. PubMed 32149760 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03600259
Lead sponsor
Tianjin Chest Hospital
Responsible party
Yin Liu,MD (Director, Cardiology Department, Tianjin Chest Hospital, Tianjin Chest Hospital) — Principal investigator
First posted
Jul 26, 2018
Start date
Jan 1, 2018
Primary completion
Jan 1, 2023 (estimated)
Completion
Dec 1, 2023 (estimated)
Last update
Nov 2, 2022

Study contacts

Yin Liu, M.D
Contact
tami2018@163.com
+86-13502152283
Jixiang Wang, PHD
Contact
tami2018@163.com
+86-13752068790
Yin Liu, M.D
principal investigator · Tianjin Chest Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Myocardial Infarction →

Other studies from this sponsor

Tianjin Chest Hospital

Start the discussion